Mycoplasma pneumonia (MP), also known as M.pneumonia, is a contagious respiratory infection spread through direct contact with infected respiratory secretions. It’s also called “walking pneumonia” because the bacteria that cause it can spread rapidly in public places. The airborne spread of the infectious bacterium Mycoplasma pneumonia poses a risk to otherwise healthy people. Mycoplasma diagnostics has been noted as a rapidly developing and growing sector of the in-vitro diagnostic market in recent years. A stethoscope is used to detect abnormal heart and lung sounds in the early stages of MP diagnosis. A physician may order a chest X-ray, CT scan, or blood tests to further diagnose a patient with an infection.
The global Mycoplasma Diagnostics Market is anticipated to expand in scope, speed of growth, and vitality by both therapists and researchers. The World Health Organization (WHO), an international health agency, reports that the United States is home to nearly 600 diagnosis centers and about 200 independent working research labs capable of mycoplasma diagnosis. In addition, the Austrian Research Promotion agency to (FFG) invests in part in R&D for MP Diagnosis.
Ask Us to Get Your Sample Copy Of The Report, Covering TOC and Regional Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/763
Mycoplasma diagnostics are expected to see significant growth due to the prevalence of lung and respiratory diseases
Opportunities in the mycoplasma diagnostics market have arisen in response to the rising prevalence of respiratory tract infections around the world, and the leading providers of mycoplasma diagnostics devices anticipate that rising demand for improved diagnosis will drive growth in the global market in the near future. There has been an increase in the number of deaths caused by respiratory diseases, pulmonary sickness, and tuberculosis, and this trend is expected to continue, as reported by the Forum of the International Respiratory Society in 2014. This is expected to stimulate growth of the mycoplasma diagnostic market.
The rising number of elderly people who are suffering from respiratory illness is one of the main factors driving the mycoplasma diagnostics market upward. The World Health Organization (WHO) estimates that 33.5% of the elderly population has serious problems with their respiratory system. Mycoplasma diagnostics could see global growth as effective diagnosis becomes increasingly important in the fight against chronic respiratory disorders.
Mycoplasma diagnostics device market growth is being hindered by a lack of education about the devices
The worldwide market for mycoplasma diagnostic tools is expanding. However, the mycoplasma diagnostics market may have to deal with some unfavorable obstacles. The main misguided reason to restrain expansion is a lack of public awareness of the benefits of diagnosis. In addition, the high price of Mycoplasma Diagnosis equipment is a factor that is reducing its demand and utility.
The growing demand for advanced methods is expected to be a key factor propelling the Mycoplasma Diagnostics market
Recent developments in technology, like Polymerase Chain Reaction (PCR), DNA staining, and Immunoassay, have reportedly captured the majority of the market as of 2016, as reported by the World Health Organization. But there has been a dramatic increase in the application of methods like ELISA and RIA. The pharmaceutical and diagnostic industries regularly employ such methods because of their low cost and widespread availability.
Mycoplasma Diagnostics Market-Regional Analysis
Markets for mycoplasma diagnostics are broken down into several sub segments based on geography: North America, Europe, the Middle East and Africa, Asia-Pacific, and Latin America.
North America accounts for 35.6% of global sales of Mycoplasma diagnostics, as reported by the World Health Organization in 2015. Mycoplasma infections are on the rise in the Asia-Pacific region, where in 2016 an estimated 7.4 Mn people were affected by them, according to the World Health Organization. The rising prevalence of respiratory tract infections and mortality rates in the Asia Pacific region bode well for the Mycoplasma Diagnostics Market. The Asia-Pacific region is expected to continue to lead the global market, and its key players and government are optimistic about the prospects for growth in the coming years.
Mycoplasma Diagnostics Device Market-Competitive landscape
Agilent Technologies, American Type Culture Collection (ATCC), Thermo Fisher Scientific, Takara Holding, PromoCell GmbH, Merck KGaA, Lonza Group, Savyon Diagnostics, Tecan Group, Charles River Laboratories International, F Hoffmann-La Roche, and Sartorius Stedim BioOutsource are some of the key players in the global mycoplasma diagnostics market. Companies like Thermo Fisher Scientific and Merck KGaA, which play a significant role in the global mycoplasma diagnostics industry, hold roughly 23% of the global market, which increases the opportunities towards profitable and global market insights in Mycoplasma Diagnostics.
Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/763
- With 510(k) clearance from the FDA, QIAGEN introduced the QIAstat-Dx Respiratory Panel in May 2019 for the instantaneous qualitative detection and recognition of multiple respiratory pathogens such as viruses and bacteria
- .In July of 2018, ATCC introduced a PCR-based service for monitoring cell cultures for mycoplasma contamination. The STR Profiling Service is a part of ATCC’s expanding service portfolio that helps verify the identity of cell lines used during basic and translational research.
- In 2018, Konica Minolta, Inc. established a wholly-owned subsidiary in Japan called Konica Minolta Precision Medicine Japan, Inc., whose job it is to promote expensive diagnostic equipment and medical testing services in the field of precision medicine. Using data gleaned from a patient’s DNA and other biomarkers, “precision medicine” doctors tailor care to individual patients.
- Mycoplasma pneumonia antigen rapid diagnostic test kit, developed by GENESIS in 2016, can detect the antigen of the P1 gene of M. pneumonia in specimens taken from patients suspected of having M. pneumonia infection.
- Merck entered the market for mycoplasma diagnostic devices after purchasing Sigma-Aldrich Co., a global leader in the life science sector, in 2015.
Mycoplasma Diagnostics Device Market-Taxonomy
The market for Mycoplasma diagnostics worldwide is split up by application, target audience, and geographical location
- Polymerase Chain Reaction (PCR)
- RIA (Radio immuno assay)
- ELISA (Enzyme linked immune sorbant assay)
- DNA staining
- Microbial culture techniques
By End User
- Diagnostic laboratories
- North America
- Asia Pacific
- Latin America
- Middle East
Direct Purchase This Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/763
Table of Contents with Major Points:
- Key Findings
- Definitions and Assumptions
- Definition of Mycoplasma Diagnostics Market
- Market Dynamics
- Trends and Developments
- Key Emerging Trends
- Key Developments Mergers and Acquisition
- New Product Launches and Collaboration
- Partnership and Joint Venture
- Latest Technological Advancements
- Insights on Regulatory Scenario
- Porters Five Forces Analysis
Qualitative Insights Impact of COVID-19 on Global Mycoplasma Diagnostics Market
- Supply Chain Challenges
- Steps taken by Government/Companies to overcome this impact
- Potential opportunities due to COVID-19 outbreak
- Data Sources
Why Choose Coherent Market Insights?
☛ Identified business opportunities – Our market research report can be used to analyze potential markets and new products. It can give information about customer needs, preferences, and attitudes. Also, it compare products and services.
☛ A clear understanding of your customers – A market report gives company’s marketing department an in-depth picture about customers’ needs and wants. This knowledge can be used to improve products, prices, and advertising.
☛ Clear data-driven insights – Our Market research encompasses a wide range of activities, from determining market size and segment to forecasting demand, and from identifying competitors to monitoring pricing. All of these are quantified and measurable which means that gives you a clear path for building unique decisions based on numbers.
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027